Trial Profile
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Sep 2022
Price :
$35
*
At a glance
- Drugs Folate-fluorescein isothiocyanate conjugate (Primary)
- Indications Adenocarcinoma; Carcinoma; Ovarian cancer
- Focus Diagnostic use; Registrational
- Sponsors On Target Laboratories
- 12 Sep 2022 Results published in the On Target Laboratories Media Release.
- 07 Sep 2022 Results assessing safety and efficacy of pafolacianine , published in the Journal of Clinical Oncology
- 29 Nov 2021 Results published in the Media Release